Yıl: 2014 Cilt: 3 Sayı: 3 Sayfa Aralığı: 1427 - 1441 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

İnsan Prostat Kanseri Hücre Serilerinde Apelin-13'ün Etkileri

Öz:
Prostat kanseri erkeklerde görülen en yaygın kanser tiplerinden biridir. Değişik tipteki çoğu kanser türleri için kesin çözüm olabilecek bir tedavi yöntemi tam olarak geliştirilememiştir. Yağ dokudan salgılanan apelin, APJ reseptörüne bağlanarak etkilerini ortaya koymaktadır. Artan yağ doku kitlesi ile obezite gelişmekte ve obeziteye bağlı apelin salgısının da arttığı bilinmektedir. Obezitenin kanser gelişiminde bir risk faktörü olması, hem apelinin hem de reseptörünün testis ve prostat dokusunda yaygın bir şekilde bulunması apelinin prostat kanseri üzerinde önemli etkilerinin olabileceğini akla getirmektedir. Bu çalışmada ilk olarak, apelin-13'ün 0.1, 1 ve 10 nM'lik konsantrasyonları, testosteron hormonunun ise 1, 10, 100 nM'lik konsantrasyonları LNCaP (androjen reseptör pozitif) ve DU-145 (androjen reseptör negatif) insan prostat kanseri hücre serilerine ayrı ayrı uygulandı. Daha sonra testosteron hormonunun 1, 10, 100 nM'lik konsantrasyonları ile 24 saat inkübe edilen prostat kanser hücrelerine apelin-13'ün 10 nM'lik dozu uygulandı ve 24 saat inkübasyona bırakıldı. Apelin13 ve testosteron hormonlarının prostat kanseri hücre canlılığı üzerine etkileri, 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay ile belirlendi. Çalışma sonunda uygulanan apelin-13 ve testosteronun LNCaP hücre canlılığını arttırdığı (p<0.001), DU-145 hücre canlılığını ise etkilemediği belirlendi. Apelin-13 ile testosteronun birlikte uygulandığı LNCaP hücre serilerinde, sadece apelin ve testosteron uygulamalarına kıyasla daha güçlü bir proliferatif etki meydana geldiği (p<0.001) ancak DU-145 hücrelerinde herhangi bir etkinin olmadığı gözlendi. Sonuç olarak, apelin-13, LNCaP hücre serilerinde testosteronun etkisine benzer şekilde poliferasyona sebep olurken, DU-145 hücreleri üzerine herhangi bir etki göstermedi. Bu sonuçlar, apelin-13'ün etkilerini testosteronun etkisine benzer şekilde androjen reseptör bağımlı bir mekanizma üzerinden ortaya koyduğuna delil teşkil etmektedir.
Anahtar Kelime:

Konular: Biyoloji

Effects of Apelin-13 on Human Prostate Cancer Lines

Öz:
Prostate cancer is one of the most prevalent type of cancer in men. The exact solution for the treatment of different types of cancers has not been fully elucideted. Apelin secreted from adipose tissue reveals its effects by binding to APJ receptor. Obesity develops together with increased adipose tissue, and the increase of obesity related-apelin secretion is known. Obesity is a risk factor in the development of cancer, and considering both apelin and its receptor widely localized in the tissues of testis and prostate and apelin may have significant effects on prostate cancer. In the present study, 0.1, 1 and 10 nM concentrations of apelin-13 and three different testosterone concentrations (1, 10 and 100 nM) were separately aplied to human prostate cancer cells with LNCaP (androgen receptor positive) and DU-145 (androgen receptor negative). Then 1, 10 and 100 nM concentrations of testosterone hormone and 10 nM dose of apelin-13 incubated for 24 h in the prostate cancer cells were administrated and were allowed to incubate for 24 h. Effects of apelin-13 and testosterone on prostate diphenyltetrazolium bromide (MTT) assay. At the end of the experiment, DU-145 did not affected cell viability while the treatment with apelin -13 and testosterone increased the viability of LNCaP cells (p<0.001). The proliferation effect was strongly occured when LNCaP cells were treated with together apelin-13 and testosterone (p<0.001) but, no effect was observed in DU-145 cells. In conclusion; apelin-13 had similar proliferative effects with testosterone on LNCaP cells, but had no effect on DU-145 cells. These results suggest that the effects of apelin-13 are similar to testosterone, and it realises their effects through an androgen receptor-dependent mechanism.
Anahtar Kelime:

Konular: Biyoloji
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. TC Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu: http://www.kanser.gov.tr/dairefaaliyetleri/kanser-istatistikleri.html access date 11.03.2014
  • 2. Beytur A, Tekin S, Keleştemur T, Ergin Z, Sandal S. Yeni sentezlenen bir tiyosemikarbazon türevinin prostat kanseri hücre kültürleri üzerine antikanserojenik özelliklerinin belirlenmesi: In vitro bir çalışma. F.Ü.Sağ.Bil.Tıp Derg. 2011;25(1): 25- 32.
  • 3. Genc Z, Tekin S, Sandal S, Sekerci M, Genc M. Synthesis and DFT studies of structural and some spectral parameters of nickel(II) complex with 2-(2- hydroxybenzoyl)-N-(1-adamantyl) hydrazine carbothioamide. Research on Chemical Intermediates. 2014:1-12.
  • 4. Koyunoğlu F, Tekin S, Konar V, Sandal S. İnsan meme kanseri hücre serileri (MCF-7) üzerine apelin-13'ün etkilerinin araştırılması: In vitro bir çalışma. İnönü Üniversitesi Sağlık Bilimleri Dergisi. 2013;1(1):23-8.
  • 5. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM, West DW, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst. 1995;87(9):652-61.
  • 6. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11: 1388-413.
  • 7. Chan JM, Stampfer MJ, Giovannucci EL. What causes prostate cancer? A brief summary of the epidemiology. Seminars in Cancer Biology. 1998;8(4):263-73.
  • 8. Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostatespecific analysis ratio, age-specific reference ranges, and PSA density. Urology. 1995; 46(6):779-84.
  • 9. Vis AN, Schroder FH. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int. 2009;104(4):438-48.
  • 10. Tunçkıran A, Bozlu B. Hormona dirençli prostat kanseri hastalarında dosetaksel, estramustin fosfat ve karboplatin kombinasyonunun Faz-2 çalışması. European Urology. 2007;51:1252-8.
  • 11. Oh WK. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer. 2000; 88(12 Suppl): 3015-21.
  • 12. Calabrò F, Sternberg CN. Current Indications for Chemotherapy in Prostate Cancer Patients. European Urology. 2007;51(1):17-26.
  • 13. Nalabolu MR, Palasamudram K, Jamil K. Adiponectin and Leptin Molecular Actions and Clinical Significance in Breast Cancer. Int J Hematol Oncol Stem Cell Res. 2014; 8(1):31-40.
  • 14. King B, Jiang Y, Su X, Xu J, Xie L, Standard J, Wang W. Weight control, endocrine hormones and cancer prevention. Exp Biol Med (Maywood). 2013;238(5):502-8.
  • 15. Sandal S, Tekin S. Adipoz Dokudan Salgılanan Bir Hormon: Apelin. İnönü Üniversitesi Sağlık Bilimleri Dergisi. 2013;1:55-62.
  • 16. Aktaş G, Şit M, Tekçe H. Yeni adipokinler: Leptin, Adiponektin ve Omentin. Abant Medical Journal. 2013;2(1):56-62.
  • 17. Park SH, Chang SN, Baek MW, Kim DJ, Na YR, Seok SH, Lee BH, Kim KS, Park JH. Effects of dietary high fat on prostate intraepithelial neoplasia in TRAMP mice. Lab Anim Res. 2013;29(1):39-47.
  • 18. Catalan V, Gomez-Ambrosi J, Rodriguez A, Fruhbeck G. Adipose tissue immunity and cancer. Front Physiol. 2013;4:275.
  • 19. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:291546.
  • 20. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou M-X, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ Receptor. Biochemical and Biophysical Research Communications. 1998;251(2):471-6.
  • 21. Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, Kitada C, Honda S, Kurokawa T, Onda H, Nishimura O, Fujino M. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem. 2000;275(28):21061-7.
  • 22. Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S, Nishizawa N, Kitada C, Onda H, Nishimura O, Fujino M. Molecular properties of apelin: tissue distribution and receptor binding. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2001;1538(2-3):162-71.
  • 23. De Falco M, De Luca L, Onori N, Cavallotti I, Artigiano F, Esposito V, De Luca B, Laforgia V, Groeger AM, De Luca A. Apelin expression in normal human tissues. In Vivo. 2002;16(5):333-6.
  • 24. Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, Fujimiya M. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99(2-3):87-92.
  • 25. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacology & Therapeutics. 2005;107(2):198-211.
  • 26. Than A, Cheng Y, Foh LC, Leow MK, Lim SC, Chuah YJ, Kang Y, Chen P. Apelin inhibits adipogenesis and lipolysis through distinct molecular pathways. Mol Cell Endocrinol. 2012;362(1-2):227-41.
  • 27. Krist J, Wieder K, Kloting N, Oberbach A, Kralisch S, Wiesner T, Schon MR, Gartner D, Dietrich A, Shang E, Lohmann T, Dressler M, Fasshauer M, Stumvoll M, Bluher M. Effects of weight loss and exercise on apelin serum concentrations and adipose tissue expression in human obesity. Obes Facts. 2013;6(1):57-69.
  • 28. Zelenko Z, Gallagher EJ. Diabetes and Cancer. Endocrinol Metab Clin North Am. 2014;43(1):167-85.
  • 29. Rayalam S, Della-Fera MA, Kasser T, Warren W, Baile CA. Emerging role of apelin as a therapeutic target in cancer: a patent review. Recent Pat Anticancer Drug Discov. 2011;6(3):367-72.
  • 30. Picault FX, Chaves-Almagro C, Projetti F, Prats H, Masri B, Audigier Y. Tumour coexpression of apelin and its receptor is the basis of an autocrine loop involved in the growth of colon adenocarcinomas. Eur J Cancer. 2014;50(3):663-74.
  • 31. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986;89(2):271-7.
  • 32. Hor kov Kn, ov ı kov A, Seemannov Z, Syrov D, Bu nyov Kn, Drobn Z, Feren ı k M. Detection of drug-induced, superoxide-mediated cell damage and its prevention by antioxidants. Free Radical Biology and Medicine. 2001;30(6):650-64.
  • 33. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63.
  • 34. Cimino S, Sortino G, Favilla V, Castelli T, Madonia M, Sansalone S, Russo GI, Morgia G. Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid Med Cell Longev. 2012;2012:632959.
  • 35. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-36.
  • 36. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5): 277-300.
  • 37. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005; 16(3):481-8.
  • 38. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am. 1999;26(2):263-73.
  • 39. Bisson JF, Hidalgo S, Simons R, Verbruggen M. Preventive Effects of Lignan Extract from Flax Hulls on Experimentally Induced Benign Prostate Hyperplasia. J Med Food. 2014. [Epub ahead of print]
  • 40. Chen G, Liu H, Cheng F. Fangjihuangqi tang improved lower urinary tract dysfunction in benign prostatic hyperplasia rats model. J Tradit Chin Med. 2013; 33(3):349-54.
  • 41. Bhargava S. Increased DHT levels in androgenic alopecia have been selected for to protect men from prostate cancer. Med Hypotheses. 2014;82(4):428-32.
  • 42. Ming DS, Pham S, Deb S, Chin MY, Kharmate G, Adomat H, Beheshti EH, Locke J, Guns ET. Pomegranate extracts impact the androgen biosynthesis pathways in prostate cancer models in vitro and in vivo. J Steroid Biochem Mol Biol. 2014;143C:19-28.
  • 43. Uzunoglu S, Karaca B, Atmaca H, Kisim A, Karabulut B, Uslu R. Targeting Bcl-2 Protein to Enhance Chemosensitivity of Hormone Refractory Prostate Cancer Cell Line, DU-145 by a Synergistic Combination of Docetaxel and Gossypol. Turkiye Klinikleri Tip Bilimleri Dergisi. 2011;31(4):859-66.
  • 44. Gimble JM. Adipose tissue-derived therapeutics. Expert Opin Biol Ther. 2003;3(5): 705-13.
  • 45. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009;54(9):1847-56.
  • 46. Liu Y, Song CY, Wu SS, Liang QH, Yuan LQ, Liao EY. Novel adipokines and bone metabolism. Int J Endocrinol. 2013;2013:895045.
  • 47. Donohoe CL, O'Farrell NJ, Doyle SL, Reynolds JV. The role of obesity in gastrointestinal cancer: evidence and opinion. Therap Adv Gastroenterol. 2014;7(1): 38-50.
  • 48. Popkin BM. Understanding global nutrition dynamics as a step towards controlling cancer incidence. Nat Rev Cancer. 2007;7(1):61-7.
  • 49. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505): 425-32.
  • 50. Hebbard L, Ranscht B. Multifaceted roles of adiponectin in cancer. Best Pract Res Clin Endocrinol Metab. 2014;28(1):59-69.
  • 51. Kim JG, Kim EO, Jeong BR, Min YJ, Park JW, Kim ES, Namgoong IS, Kim YI, Lee BJ. Visfatin stimulates proliferation of MCF-7 human breast cancer cells. Mol Cells. 2010;30(4):341-5.
  • 52. Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, Rago V, Montanaro D, Maggiolini M, Panno ML, Ando S. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem. 2004;279(19): 19908-15.
  • 53. Somasundar P, Yu AK, Vona-Davis L, McFadden DW. Differential effects of leptin on cancer in vitro. The Journal of surgical research. 2003;113(1):50-5.
  • 54. Arditi JD, Venihaki M, Karalis KP, Chrousos GP. Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm Metab Res. 2007;39(1):9-13.
  • 55. Sorli SC, Le Gonidec S, Knibiehler B, Audigier Y. Apelin is a potent activator of tumour neoangiogenesis. Oncogene. 2007;26(55):7692-9.
  • 56. Berta J, Kenessey I, Dobos J, Tovari J, Klepetko W, Jan Ankersmit H, Hegedus B, Renyi-Vamos F, Varga J, Lorincz Z, Paku S, Ostoros G, Rozsas A, Timar J, Dome B. Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis. J Thorac Oncol. 2010;5(8):1120-9.
  • 57. Heo K, Kim YH, Sung HJ, Li HY, Yoo CW, Kim JY, Park JY, Lee UL, Nam BH, Kim EO, Kim SY, Lee SH, Park JB, Choi SW. Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients. Oral Oncol. 2012;48(6):500-6.
  • 58. Cui RR, Mao DA, Yi L, Wang C, Zhang XX, Xie H, Wu XP, Liao XB, Zhou H, Meng JC, Yuan LQ, Liao EY. Apelin suppresses apoptosis of human vascular smooth muscle cells via APJ/PI3-K/Akt signaling pathways. Amino Acids. 2010;39(5): 1193- 200.
  • 59. Xie H, Yuan L-Q, Luo X-H, Huang J, Cui R-R, Guo L-J, Zhou H-D, Wu X-P, Liao EY. Apelin suppresses apoptosis of human osteoblasts. Apoptosis. 2007;12(1): 247-54.
  • 60. Zeng XXI, Wilm TP, Sepich DS, Solnica-Krezel L. Apelin and Its Receptor Control Heart Field Formation during Zebrafish Gastrulation. Developmental Cell. 2007; 12(3):391-402.
APA Tekin S, SANDAL S, ÇOLAK C (2014). İnsan Prostat Kanseri Hücre Serilerinde Apelin-13'ün Etkileri. , 1427 - 1441.
Chicago Tekin Suat,SANDAL Süleyman,ÇOLAK Cemil İnsan Prostat Kanseri Hücre Serilerinde Apelin-13'ün Etkileri. (2014): 1427 - 1441.
MLA Tekin Suat,SANDAL Süleyman,ÇOLAK Cemil İnsan Prostat Kanseri Hücre Serilerinde Apelin-13'ün Etkileri. , 2014, ss.1427 - 1441.
AMA Tekin S,SANDAL S,ÇOLAK C İnsan Prostat Kanseri Hücre Serilerinde Apelin-13'ün Etkileri. . 2014; 1427 - 1441.
Vancouver Tekin S,SANDAL S,ÇOLAK C İnsan Prostat Kanseri Hücre Serilerinde Apelin-13'ün Etkileri. . 2014; 1427 - 1441.
IEEE Tekin S,SANDAL S,ÇOLAK C "İnsan Prostat Kanseri Hücre Serilerinde Apelin-13'ün Etkileri." , ss.1427 - 1441, 2014.
ISNAD Tekin, Suat vd. "İnsan Prostat Kanseri Hücre Serilerinde Apelin-13'ün Etkileri". (2014), 1427-1441.
APA Tekin S, SANDAL S, ÇOLAK C (2014). İnsan Prostat Kanseri Hücre Serilerinde Apelin-13'ün Etkileri. Medicine Science, 3(3), 1427 - 1441.
Chicago Tekin Suat,SANDAL Süleyman,ÇOLAK Cemil İnsan Prostat Kanseri Hücre Serilerinde Apelin-13'ün Etkileri. Medicine Science 3, no.3 (2014): 1427 - 1441.
MLA Tekin Suat,SANDAL Süleyman,ÇOLAK Cemil İnsan Prostat Kanseri Hücre Serilerinde Apelin-13'ün Etkileri. Medicine Science, vol.3, no.3, 2014, ss.1427 - 1441.
AMA Tekin S,SANDAL S,ÇOLAK C İnsan Prostat Kanseri Hücre Serilerinde Apelin-13'ün Etkileri. Medicine Science. 2014; 3(3): 1427 - 1441.
Vancouver Tekin S,SANDAL S,ÇOLAK C İnsan Prostat Kanseri Hücre Serilerinde Apelin-13'ün Etkileri. Medicine Science. 2014; 3(3): 1427 - 1441.
IEEE Tekin S,SANDAL S,ÇOLAK C "İnsan Prostat Kanseri Hücre Serilerinde Apelin-13'ün Etkileri." Medicine Science, 3, ss.1427 - 1441, 2014.
ISNAD Tekin, Suat vd. "İnsan Prostat Kanseri Hücre Serilerinde Apelin-13'ün Etkileri". Medicine Science 3/3 (2014), 1427-1441.